Sutro sets up SAB
This article was originally published in Scrip
Sutro Biopharma, a San Francisco-based firm developing novel protein therapeutics, has appointed a new scientific advisory board comprising two members: James Wells, professor in pharmaceutical sciences and director of the Small Molecule Discovery Center at the University of California, San Francisco; and Professor James Swartz, a director and founder of Sutro Biopharma and a professor in the school of engineering at Stanford University. Professor Wells will serve as chair of the SAB.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.